ABUS

Arbutus Biopharma Corporation Common Stock

3.65

USD

-0.02

-0.41%

Nov 06, 15:48 UTC -5

Closed

After-Market

3.65

0.00

0.00%

Arbutus Biopharma Corporation Common Stock (ABUS) Earnings

ABUS Earnings Reports

Positive Surprise Ratio

ABUS beat 23 of 43 last estimates.

53%

Next Report

Next Week

Date of Next Report

Nov 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

$1.02M

-$0.02

Implied change from Q2 26 (Revenue/ EPS)

+0.59%

-33.33%

Implied change from Q3 25 (Revenue/ EPS)

+92.82%

-50.00%

Arbutus Biopharma Corporation Common Stock earnings per share and revenue

On Aug 12, 2026, ABUS reported earnings of -0.03 USD per share (EPS) for Q2 26, missing the estimate of -0.02 USD, resulting in a -47.06% surprise. Revenue reached 1.01 million, compared to an expected 714.00 thousand, with a 42.02% difference. The market reacted with a -1.71% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 1.02 million USD, implying an decrease of -33.33% EPS, and increase of 0.59% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Novavax Inc

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.34

Actual

-$0.19

Surprise

+44.56%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.31

Actual

$1.06

Surprise

+232.50%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Monte Rosa Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.29

Actual

$0.03

Surprise

+110.09%

PUMA BIOTECHNOLOGY INC

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.15

Surprise

+63.40%

Allogene Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.15

Actual

-$0.15

Surprise

+0.33%

Arcturus Therapeutics Holdings Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.69

Actual

-$0.26

Surprise

+62.44%

Anika Therapeutics Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

$0.06

Actual

$0.28

Surprise

+373.86%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Vera Therapeutics, Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.65

Actual

-$1.30

Surprise

+21.33%

FAQ

What were Arbutus Biopharma Corporation Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Arbutus Biopharma Corporation Common Stock reported EPS of -$0.03, missing estimates by -47.06%, and revenue of $1.01M, 42.02% above expectations.

How did the market react to Arbutus Biopharma Corporation Common Stock's Q2 2026 earnings?

The stock price moved down -1.71%, changed from $4.67 before the earnings release to $4.59 the day after.

When is Arbutus Biopharma Corporation Common Stock expected to report next?

The next earning report is scheduled for Nov 11, 2026.

What are the forecasts for Arbutus Biopharma Corporation Common Stock's next earnings report?

Based on 3 analysts, Arbutus Biopharma Corporation Common Stock is expected to report EPS of -$0.02 and revenue of $1.02M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.